UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Introduction

Diabetes mellitus (DM) is a substantial risk factor for pancreatic cancer (PC). Concurrently, aspirin has been implicated to have chemopreventive effect against cancer of digestive system. However, studies regarding the effect of aspirin on mitigating PC risk among DM populations remain scant.

Aims & Methods

We aimed to examine whether regular use of aspirin was associated with a reduced risk of PC after adjusting for known risk factors among type 2 diabetes (T2D) patients.

This was a territory-wide, retrospective cohort study of newly diagnosed T2D patients between 2001 and 2015 in Hong Kong. Exclusion criteria included <18 years old, history of PC, pancreatic neuroendocrine tumor, serous cystadenoma, chronic or acute pancreatitis, and pancreatic cyst. The outcome of interest was pancreatic cancer. Adjusted hazard ratios (aHRs) for outcomes associated with aspirin use were calculated using multivariable Cox regression models. Aspirin use was treated as a time-varying covariates (≥180 days use at each yearly interval) in the analysis to address and minimize immortal-time bias.

Results

We identified 342,920 T2D patients (52.2% male, mean age: 58.8±11.6 years), including 43,634 (12.7%) aspirin users. During a mean follow-up of 11.1±4.2 years, 1,114 (0.3%) patients developed PC, with an incidence rate of 2.92 per 10,000 person-years. Aspirin use was associated with a reduced PC risk (HR 0.55, 95%CI 0.46-0.66). When compared with the reference group (never use), a lower risk was observed with increasing frequency, with the exception of daily use. In addition, longer durations of aspirin use were associated with a progressively lower PC risks (HR 0.83, 95%CI 0.71-0.96, for less than five years of use; HR 0.56, 95%CI 0.45-0.69, for five to ten years of use; and HR 0.27, 95%CI 0.20-0.36, for ten or more years of use. Both frequency and duration of aspirin use demonstrated statistically significant trends (P_trend <0.001) (Table 1).

Table 1. HRs and 95% CIs for the association between frequency and duration of aspirin use and risk of pancreatic cancer

Aspirin use	No. of patients (n=342,920)	No. of PC (n=1,114)	HR (95% CI)	P*	P_trend^*
Frequency Never user	219,674	736	ref	-	<0.001
<Monthly use	13,809	52	0.66 (0.50-0.88)	0.004
Monthly to <weekly use	13.274	44	0.59 (0.43-0.80)	<0.001
Weekly to <daily use	73,232	201	0.54 (0.46-0.63)	<0.001
Daily use	22,931	81	0.90 (0.69-1.16)	0.401
Duration (years) Never user	219,674	736	ref	-	<0.001
<5	54,029	223	0.83 (0.71-0.96)	0.015
5 - <10	40,003	99	0.56 (0.45-0.69)	<0.001
≥10	29,214	56	0.27 (0.20-0.36)	<0.001

*Cox proportional hazards model was used to calculate the P values. Adjusted covariates included age, sex, lifestyle factors (body mass index, smoking, and alcohol use), metabolic disorders (dyslipidemia and hypertension), time-weighted mean HbA1c, DM complications, cardiovascular diseases, other anti-diabetic medications, non-aspirin non-steroidal anti-inflammatory drugs, and statins.
Abbreviation: CI, confidence interval; HR, hazard ratios; PC, pancreatic cancer; ref, reference

Conclusion

Aspirin use was associated with a reduction in PC risk among T2D patients, which was dependent on both frequency and duration of use. Notably, this trend was observed with increased frequency of use, with the exception of daily use. Further studies are warranted to assess long-term effects and potential risks.

REDUCED RISK OF PANCREATIC CANCER ASSOCIATED WITH REGULAR ASPIRIN USE IN TYPE 2 DIABETES PATIENTS

Jing Tong Tan 1, Ka Shing Cheung 2, Xianhua Mao 3, Wai-Kay Seto 2

1 The University of Hong Kong, Hong Kong, Hong Kong

2 The University of Hong Kong, Hong Kong, Hong Kong|||The University of Hong Kong-Shenzhen Hospital, Shenzhen, China

3 The University of Hong Kong-Shenzhen Hospital, Shenzhen, China|||The University of Hong Kong, Hong Kong, Hong Kong

Conference

UEG Week Vienna 2024

Topics

Pancreas

Submission format

Abstract

Session

Pancreatic cancer: Cinical (Posters)

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Besides stage, age and CA19-9 there is limited knowledge on “patient-related factors” associated with chemotherapy response for Pancreatic Ductal Adenocarcinoma (PDAC) patients. Smoking worsens chemotherapy response in other tumours and seems to promote tumor progression in PDAC preclinical models, but data in human PDAC are scanty.

Aims & Methods

PDAC patients were prospectively enrolled at diagnosis with exposome and clinical data registered, and tumors sampled for research purpose during Endoscopic Ultrasound (EUS). Patients were then followed-up to register chemotherapy treatment [whether Folfirinox (F), Abraxane-gemcitabine (AG) or a combination of cisplatin, abraxane, capecitabine and gemcitabine (PAXG)] and evaluate disease control rate (DCR) at 6-months (DCR-6), Progression-Free-Survival (PFS) and Overall-Survival (OS). We also explored transcriptomic signatures associated with smoking on a subset of EUS-acquired PDAC samples undergoing RNA-sequencing, with differential gene expression (DGE) analysis and pathways analysis performed. Furthermore, in vitro analyses with PDAC cell lines CAPAN-1 were treated with Folfirinox or gemcitabine with/without the nicotine compound 4-(Methylnitrosoamino)-1-(3-pyridinyl)-1-butanone to evaluate in vitro effects.

Results

326 patients treated with chemotherapy of interest were analyzed. Median age was 65, with 51.5% being males. Disease’s resectability at diagnosis was 10.4% resectable, 37.7% borderline-resectable, 26.9.% locally-advanced, 24.8% metastatic. AG was used in 42.3% of patients, PAXG in 25.7%, Folfirinox in 31.9%. DCR-6 was 57.9% in current smokers vs 70.4% in never-/ex-smokers (p=0.05). Current smoking was associated with a lack of DCR-6 at adjusted multivariable analysis (OR=1.99; 95%CI:1.1-3.5; p=0.01). At subgroup analysis, this was confirmed only for Folfirinox patients, with DCR-6 being 46.2% for current smokers vs 75.6% for non-current smokers(p=0.007). Current smokers had a significantly shorter PFS (5 vs 13 months; HR:1.79; 95%CI:1.13-3.21; p=0.01) and OS (24 vs 34; HR 1.93; 95%CI: 1-3.67; p=0.04) compared to non-smokers at adjusted multivariable analysis.
At transcriptomic analysis on a subset of 84 patients, current smokers were more prevalent in patients developing the more aggressive basal-like subtype (50% vs 15%; p=0.03), had lower expression of the classical marker GATA6 (3.27 vs 3.92; p=0.03) as also different activated pathways such as activated MAPK signalling, Axon guidance, Hypoxia and epithelial-mesenchymal-transition signalling among the others.
At in vitro experiments, for cell survival analysis, CAPAN-1 PDAC cells showed a significant reduced response to Folfirinox treatment when treated in combination with nicotin compounds, which was not observed for gemcitabine alone or in combination.

Conclusion

Collectively, our results consistently point towards a deleterious effect of smoking on response to Folfirinox regimen. Clinical data show that current smoking is a predictive factor for lower DCR-6, shorter PFS and OS; transcriptomic analyses show different gene expressions between smokers and non-smokers, with a transition toward reduced expression of classical phenotype and activation of inflammatory and pro-mesenchimal pathways. In vitro experiments support the negative effect of smoking on the response to Folfirinox. Smoking should be considered as a covariate to be investigated when choosing chemotherapy regimens in patients with PDAC, and patients should be discouraged to continue smoking.

SMOKING IMPAIRS THE RESPONSE TO FOLFIRINOX IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA: RESULTS FROM CLINICAL, TRANSCRIPTOMICS AND IN VITRO ANALYSES

Livia Archibugi 1, Pilar Lazzano 2, Veronica Ruta 3, Ruggero Ponz de Leon Pisani 1, Claudia Fortunato 1, Piera Zaccari 1, Gemma Rossi 1, Matteo Tacelli 1, Maria Chiara Petrone 1, Marina Macchini 1, Giulia Orsi 1, Massimo Falconi 4, Claudio Sette 3, Michele Reni 1, Paolo Giorgio Arcidiacono 1, Gabriele Capurso 1

1 Hospital San Raffaele, Milan, Italy

2 Policlinico di Milano, Milan, Italy

3 Catholic University, Rome, Italy

4 Università Vita-Salute San Raffaele, San Raffaele, Italy

Conference

UEG Week Berlin 2025

Topics

Pancreas

Submission format

Abstract

Session

Pancreatic cancer: Treatment and outcomes (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Hormonal exposure influences cancer initiation and progression in several organs, including the pancreas. The association between gynecological factors and the onset of pancreatic adenocarcinoma (PDAC) is conflicting, with some studies showing a reduced risk of PDAC with the use of hormonal replacement therapy (HRT) or with having had a late-onset menopause. Nonetheless, the association between gynecological factors and disease prognosis has not yet been investigated. Our objective was to evaluate whether gynecological/reproductive factors affect PDAC prognosis.

Aims & Methods

This was a single-center retrospective analysis of a prospectively maintained database of PDAC patients. Risk factors were assessed via questionnaires regarding gynecologic/reproductive factors (age at menarche, menopause, years of fertility, breastfeeding, pregnancy, miscarriages, use of oral contraceptives (OC) or HRT), medical history, and prognosis were evaluated with follow-up visits and/or telephonic calls. Continuous variables were investigated using the Mann–Whitney test, and factors associated with survival probability were evaluated using Cox's proportional hazards model, adjusting for potential confounders.

Results

228 PDAC women were analyzed, with mean age at diagnosis being 68. The most frequent stages were borderline resectable (35.9%) and locally advanced (25.4%), with a median overall survival (OS) of 14 months. The age of PDAC onset for patients with previous use of OC was significantly lower than that of non-users (63 years vs. 72; p<0.0001), and OC use was associated with a trend toward increased survival (HR 0.6; 95%CI: 0.35-1.03; p=0.06). In addition, previous use of HRT was associated with a reduced risk of recurrence or progression (HR, 0.4; 95%CI: 0.26-0.99; p=0.001). No differences in survival or progression-free probability were observed with the other factors.

Conclusion

This is the first study to evaluate whether gynecological/reproductive factors are associated with the prognosis of PDAC patients, with the use of OC and HRT being the most relevant factors. Previous OC users had a significantly lower onset age for PDAC and a borderline significant association was seen with increased survival. Additionally, HRT use is associated with a reduced risk of tumor recurrence or progression. These data need to be confirmed, and the potential mechanisms need to be elucidated.

HISTORY OF USE OF ORAL CONTRACEPTIVES AND HORMONAL REPLACEMENT THERAPY SEEMS TO IMPACT PROGNOSIS OF WOMEN WITH PANCREATIC CANCER DIAGNOSIS

Gaetano Lauri 1, Livia Archibugi 1, Ruggero Ponz de Leon Pisani 1, Claudia Fortunato 1, Lilia De Carolis 1, Laura Apadula 1, Michele Reni 1, Massimo Falconi 1, Paolo Giorgio Arcidiacono 1, Gabriele Capurso 1

1 San Raffaele Hospital, Milan, Italy

Conference

UEG Week Vienna 2024

Topics

Pancreas

Submission format

Abstract

Session

Pancreatic cancer: Cinical (Posters)

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Panel Discussion: Pancreatic cancer - Extending life expectancy

Event

UEG Week Vienna 2024

Topics

Digestive Oncology Mechanisms & Personalised Medicine Pancreas Surgery

Session

Pancreatic cancer: Extending life expectancy

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

In patients with chronic pancreatitis (CP), pancreatic exocrine insufficiency (PEI) and poor nutritional intake may cause nutritional deficiencies. Guidelines advise monitoring key nutrients and supplementing is case of deficiency to prevent malnutrition-related complications. However, adherence remains low, possibly due to limited evidence on the clinical relevance of single nutrient deficiencies and the benefit of targeted supplementation. The aim of this study is to evaluate the prevalence of nutritional deficiencies in patients with CP and to identify predictors of those at highest risk. Secondary, we seek to explore association between nutritional deficiencies and malnutrition-related complications, and to provide insight into the natural course of nutritional deficiencies.

Aims & Methods

We analyzed data from the COMBO-trial, a nationwide stepped-wedged cluster randomized trial to evaluate the effect of an evidence-based algorithm for the management of CP. Measurements of fat-soluble vitamins, minerals, and albumin conducted in the outpatient clinic during the 35-month study period were included. PEI was defined as fecal elastase-1 concentration <200 µg/g or the use of pancreatic enzyme replacement therapy (PERT). The Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q), designed to evaluate the severity of PEI symptoms, was administered at four distinct time points throughout the study. Supplement use was collected from health records and patient questionnaires. Multivariate logistic regression analysis was performed for the presence of multiple deficiencies. Potential predictors included patient and disease characteristics at baseline and the mean score of the PEI-Q during follow-up.

Results

In total 409 patients were included in this study. At baseline 327 (80.0%) had PEI and PERT was used by 297 (72.6%). Nutritional deficiencies were present in 195 patients (47.7%) of which 81 (19.8%) had multiple deficiencies. The prevalence of deficiencies included vitamin A in 13/172 (7.6%) patients, vitamin D 111/289 (38.4%), vitamin E 15/168 (8.9%), vitamin K 52/88 (59.1%), iron 44/137 (32.1%) calcium 4/198 (2.0%), magnesium 24/132 (18.2%) zinc 13/67 (19.4%), selenium 4/42 (9.5%), and albumin in 41/288 (14.2%) patients. No abnormal coagulation was observed in the 20 patients with vitamin K deficiency and available INR measurements. Osteopenia was diagnosed in 110/236 (46.6%) and osteoporosis in 56/236 (23.7%). Deficiencies in vitamin K and vitamin D, micronutrients critical to bone metabolism, were not associated with osteopenia or osteoporosis. Of 44 patients with an iron deficiency, 22 (50%) were anemic. Deficiency resolved without single nutrient supplementation in 71.4% (vitamin A), 75.0% (vitamin D), 50.0% (vitamin E) , 33.3% (vitamin K), 63.6% (iron), 100% (magnesium), 80.0% (zinc) of cases. Independent predictors for multiple deficiencies were more severe PEI symptoms (OR 1.86, 1.09 – 3.17) and daily alcohol consumption (OR 2.80, 1.27 – 6.18).

Conclusion

Nutritional deficiencies are present in approximately half of the patients with CP. Most nutritional deficiencies resolve without single nutrient supplementation. Predictors for multiple nutritional deficiencies were severity of PEI symptoms and daily alcohol consumption. Therefore, nutritional deficiencies should be considered a marker of malnutrition, with treatment focused on addressing the underlying cause rather than isolated correction through single nutrient supplementation.

NUTRITIONAL DEFICIENCIES IN CHRONIC PANCREATITIS PATIENTS ARE HIGHLY PREVALENT AND ASSOCIATED WITH ALCOHOL USE AND SYMPTOMS OF EXOCRINE INSUFFICIENCY DESPITE PANCREATIC ENZYME REPLACEMENT THERAPY

Naomi D. E. Thierens 1, Florence de Rijk 2, Sofie Bai 3, Charlotte L. van Veldhuisen 4, M.P. Anten 5, Abha Bhalla 6, Pr Bos 7, Menno A. Brink 8, Wouter L. Curvers 9, BC Eijck 10, Muhammed Hadithi 11, Akin Inderson 12, Liesbeth Kager 13, Yolande Keulemans 14, Parviez Koehestanie 15, Sjoerd Kuiken 16, Alexander C. Poen 17, Rutger Quispel 18, Tessa E.H. Römkens 19, Jerome Sint Nicolaas 20, Jan Willem A Straathof 21, Adriaan Tan 22, Willem J. Thijs 23, Merel Tielemans 15, Niels G. Venneman 24, Frank P. Vleggaar 25, Rogier P. Voermans 26, Roy LJ van Wanrooij 26, Tessa Verlaan 7, Peter Van der Schaar 3, Marc G. Besselink 26, Jeanin van Hooft 12, Hjalmar C. van Santvoort 27, Pieter Jan de Jonge 28, Marco J. Bruno 29, Joost Drenth 26, Robert C. Verdonk 30

1 Radboud University Medical Center, Nijmegen, Netherlands|||St. Antonius Hospital, Nieuwegein, Netherlands

2 Erasmus University Medical Center, Rotterdam, Netherlands|||St. Antonius Hospital, Nieuwegein, Netherlands

3 St. Antonius Hospital, Nieuwegein, Netherlands

4 Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands|||St. Antonius Hospital, Nieuwegein, Netherlands

5 Sint Franciscus Hospital, Rotterdam, Netherlands

6 Haga Hospital, Den Haag, Netherlands

7 Hospital Gelderse Vallei, Ede, Netherlands

8 Meander Medical Center, Bilthoven, Netherlands

9 Catharina Hospital, Eindhoven, Netherlands

10 Spaarne Gasthuis, Hoofddorp, Netherlands

11 Maasstad Hospital, Rotterdam, Netherlands

12 Leiden University Medical Center, Leiden, Netherlands

13 Noordwest Ziekenhuisgroep, Alkmaar, Netherlands

14 Zuyderland Medical Center, Sittard, Netherlands

15 Bravis Hospital, Roosendaal, Netherlands

16 OLVG, Amsterdam, Netherlands

17 Isala, Zwolle, Netherlands

18 Reinier de Graaf Gasthuis, Delft, Netherlands

19 Jeroen Bosch Hospital, Den Bosch, Netherlands

20 Amphia Hospital, Breda, Netherlands

21 Máxima Medisch Centrum, Veldhoven, Netherlands

22 Canisius Wilhelmina Hospital, Nijmegen, Netherlands

23 Martini Hospital, Groningen, Netherlands

24 Medisch Spectrum Twente, Enschede, Netherlands

25 University Medical Center Utrecht, Utrecht, Netherlands

26 Amsterdam University Medical Center, Amsterdam, Netherlands

27 University Medical Center Utrecht, Utrecht, Netherlands|||St. Antonius Hospital, Nieuwegein, Netherlands

28 Erasmus University Medical Center, Rotterdam, Netherlands

29 University Medical Center Rotterdam, Rotterdam, Netherlands

30 St. Antonius Ziekenhuis, Nieuwegein, Netherlands

Conference

UEG Week Berlin 2025

Topics

Pancreas

Submission format

Abstract

Session

Chronic pancreatic disease: Pancreatitis and cystic fibrosis (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Contrast-enhanced endoscopic ultrasound (CEH-EUS) is a crucial imaging modality for evaluating focal pancreatic lesions. However, its interpretation often relies on subjective judgment and operator proficiency. Computer-aided color parametric imaging is a novel technique for contrast-enhanced endoscopic ultrasound that can highlight hemodynamic features of focal pancreatic lesions enabling a more objective assessment.

Aims & Methods

To explore the utility of ITM (Inflow-time Mapping)- a computer-aided color parametric imaging technique- in characterizing pancreatic focal lesions, identifying prognostic factors, and facilitating targeted management strategies in conjunction with CEH-EUS.

50 patients including 20 cases of pancreatic ductal adenocarcinomas (PDAC), 15 cases of chronic pancreatitis, 4 cases of pancreatic neuroendocrine tumors (NETs), 1 renal cell carcinoma metastasis, and 10 cystic lesions which include 2 mucinous cystadenomas (MCA), 2 serous cystadenomas (SCA), 4 pseudocysts and 2 intraductal papillary neoplasms were enrolled. All patients underwent CEH-EUS and ITM examinations of the frames obtained during the arterial phase. Before establishing the optimal starting frame for the ITM examination, a quantitative analysis was conducted on each CEH-EUS recording. Regions of interest (ROIs) were strategically positioned in either adjacent parenchyma or vascular structures. Subsequently, parameters derived from time-intensity curve (TIC) analysis, notably arrival time (AT), were estimated.
A retrospective review of CEH-EUS and ITM images involved assigning two criteria sets: (1) Routine CEH-EUS, focusing on enhancement degree and pattern, and (2) Combined CEH-EUS and ITM, emphasizing differentiation of pancreatic lesions based on contrast agent uptake speed compared to adjacent tissue. The final diagnosis was based on EUS-guided tissue acquisition.

Results

31 pancreatic lesions were initially considered PDAC based on their hypoenhanced appearance on CEH-EUS. ITM analysis could not provide additional information in 17 patients due to insufficient vascularization, while in 3 cases, ITM showed large intralesional vessels suggesting vascular invasion, supporting the PDAC diagnosis. In 11 patients, by showing no difference in the speed of UCA uptake in the enhanced regions of the lesion compared to the surrounding parenchyma, ITM analysis was able to correctly identify chronic pancreatitis, as proven by histology. In 4 patients, both CEH-EUS and ITM were consistent regarding the diagnosis of chronic pancreatitis. ITM analysis was able to provide an extensive characterization of the 4 pancreatic NETs by showing a greater speed of UCA uptake in the lesion and a centrifugal pattern of the parametric map for well-differentiated NETs. A centripetal, faster uptake of the UCA was noted in the case of pancreatic metastasis. ITM analysis also proved useful in objectively highlighting the speed and pattern of enhancement (septal/mural) of the cystic lesions included, particularly for SCAs.

Conclusion

In patients with chronic pancreatitis, where parenchymal inhomogeneity and altered local perfusion might influence the purely visual assessment, ITM complements CEH-EUS, potentially reducing unnecessary biopsies and enabling follow-up care. Additionally, for hypervascular pancreatic lesions, ITM aids in both differential diagnosis and prognostic assessment. Intralesional vessels noted on ITM images should be carefully assessed since vascular invasion can serve as an indirect marker for malignancy, particularly in hypoenhanced lesions.

ONE-YEAR UPDATE ON: DYNAMIC CONTRAST ENHANCED HARMONIC ENDOSCOPIC ULTRASOUND (CEH-EUS) AND INFLOW-TIME MAPPING: DIFFERENTIAL DIAGNOSIS AND PROGNOSIS OF FOCAL PANCREATIC LESIONS WITH COLOR PARAMETRIC IMAGING

Simona Badiu 1, Adrian Săftoiu 1, Andreea Cazimirovitz 1, Stoicescu Adriana 1

1 Elias Emergency University Hospital, Bucharest, Romania

Conference

UEG Week Vienna 2024

Topics

Pancreas

Submission format

Abstract

Session

Molecular and clinical therapies in HPB (Posters)

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

The PAN-PROMISE symptom score is the first patient-reported outcome (PROM) in acute pancreatitis (AP), and it was developed and validated in a prospective cohort of patients to be used as an endpoint in research. The aim of this study was to assess the performance of the score in a large randomized controlled trial (RCT) and its association with well-established AP endpoints.

Aims & Methods

This is an ancillary study of the WATERFALL trial, where PAN-PROMISE was evaluated at baseline, 24, 48 and 72 hours. The study examined the association between PAN-PROMISE with stablished endpoints in AP: severity, pancreatic and/or peripancreatic fat necrosis (necrosis), infected necrosis, intensive care unit (ICU) admission, persistent organ failure (POF), prolonged hospital stay and mortality. Areas under the ROC curve (AUC) were calculated and used to compare baseline PAN-PROMISE and baseline Bedside Index for Severity in AP (BISAP) for the prediction of these endpoints.

Results

248 patients from the WATERFALL trial were included. A statistically significant association was found between PAN-PROMISE and severity, necrosis, POF, ICU admission, and prolonged hospital stay at all checkpoints (p<0.05). Higher scores were also significantly associated with infected pancreatic necrosis at 24, 48, and 72h and death at baseline and 24 hours. PAN-PROMISE baseline score had a higher AUC than BISAP for severity and necrosis, but the results were not statistically significant.

Conclusion

In the context of a RCT, the PAN-PROMISE score, a patient-centered measure, has been validated with established AP outcomes and as an endpoint for future clinical trials.

USEFULNESS OF PAN-PROMISE SYMPTOM SCORE AS AN ENDPOINT IN RANDOMIZED TRIALS IN ACUTE PANCREATITIS, A VALIDATION STUDY

Lucía Guilabert 1, Karina Cárdenas-Jaén 1, James L. Buxbaum 2, Ana Garcia Garcia de Paredes 3, Lorena Bernal 1, Jose Alberto Andreu Viseras 1, Sara Pérez-Brotons 1, Alicia Vaillo-Rocamora 1, Jesús Donate Ortega 3, Eduardo Tavío Hernández 3, Édgar E. Lozada Hernández 4, Diego Hinojosa Ugarte 4, Alba Lira Aguilar 5, Patricia Pedregal-Pascual 5, Rajiv Mehta 6, Dhvani D. Adhvaryu 6, Pablo Navarro Cortés 7, Isabel Pascual-Moreno 7, Claudia Sánchez-Marin 8, Marina Cobreros del Caz 8, Idaira Fernández Cabrera 9, Fernando Casals Seoane 10, Diego Casas Deza 11, Eugenia Lauret-Braña 12, Andrea García Gómez 13, Laura María Camacho-Montaño 14, David Ruiz-Clavijo Garcia 15, Belen GONZÁLEZ DE LA HIGUERA CARNICER 15, Federico Bolado Concejo 15, Rodrigo Jover 16, José J. Mira 17, Enrique de-Madaria 18

1 Dr. Balmis General University Hospital, ISABIAL, Alicante, Spain

2 University of Southern California, Los Angeles, United States

3 Hospital Universitario Ramon y Cajal, Madrid, Spain

4 Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), León-Guanajuato, Mexico

5 Corporació Sanitària Parc Taulí, Sabadell, Spain

6 Surat Institute of Digestive Science (SIDS) Hospital and Research Centre, Surat, India

7 Hospital Clinico Universitario, Valencia, Spain

8 Marqués de Valdecilla University Hospital, Santander, Spain

9 Dr. Negrín Hospital, Las Palmas, Spain

10 Hospital Universitario de La Princesa, Madrid, Spain

11 Hospital Universitario Miguel Servet, Zaragoza, Spain

12 Central de Asturias University Hospital,Institute of Health Research of the Principality of Asturias ISPA, Oviedo, Spain

13 Lucus Augusti University Hospital, Lugo, Spain

14 Puerta del Mar University Hospital, Cadiz, Spain

15 Complejo Hospitalario Navarra, Pamplona, Spain

16 Dr. Balmis General University Hospital, ISABIAL, Alicante, Spain|||Miguel Hernández University, Elche, Spain

17 Miguel Hernández University of Elche, Elche, Spain|||Atenea Research Group, Foundation for the Promotion of Health and Biomedical Research of Valencia Region, FISABAO, San Juan, Spain

18 Miguel Hernández University, Elche, Spain|||Dr. Balmis General University Hospital, ISABIAL, Alicante, Spain

Conference

UEG Week Berlin 2025

Topics

Pancreas

Submission format

Abstract

Session

Acute pancreatitis: Complications and consequences (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Most popular content

Rate for better recommendations!